|
US3773778A
(en)
|
1972-01-24 |
1973-11-20 |
Squibb & Sons Inc |
Sulfur derivatives of pyrazolo (3,4-b)pyridines
|
|
US4107288A
(en)
|
1974-09-18 |
1978-08-15 |
Pharmaceutical Society Of Victoria |
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
PL188959B1
(pl)
|
1995-07-06 |
2005-05-31 |
Novartis Ag |
Pirolopirymidyny i sposoby ich wytwarzania
|
|
IL150524A0
(en)
|
2000-01-07 |
2003-02-12 |
Transform Pharmaceuticals Inc |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
JP4637481B2
(ja)
|
2001-10-19 |
2011-02-23 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
|
|
IL161576A0
(en)
|
2001-10-26 |
2004-09-27 |
Aventis Pharma Inc |
Benzimidazoles and analogues and their use as protein kinases inhibitors
|
|
CA2464934A1
(en)
|
2001-10-31 |
2003-05-08 |
Bayer Healthcare Ag |
Pyrimido [4,5-b] indole derivatives
|
|
AU2003234464B2
(en)
|
2002-05-03 |
2009-06-04 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
|
AU2003243318A1
(en)
|
2002-05-29 |
2003-12-19 |
Millennium Pharmaceuticals, Inc. |
Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
|
|
AU2004260689B8
(en)
|
2003-07-29 |
2008-05-15 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
WO2005034869A2
(en)
|
2003-10-08 |
2005-04-21 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
WO2005037825A2
(en)
|
2003-10-14 |
2005-04-28 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Protein kinase inhibitors
|
|
WO2005037285A1
(en)
|
2003-10-16 |
2005-04-28 |
Chiron Corporation |
2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
|
|
US20050096324A1
(en)
|
2003-11-05 |
2005-05-05 |
Zhi-Fu Tao |
Macrocyclic kinase inhibitors
|
|
US7163939B2
(en)
|
2003-11-05 |
2007-01-16 |
Abbott Laboratories |
Macrocyclic kinase inhibitors
|
|
US7642354B2
(en)
|
2004-04-13 |
2010-01-05 |
Icagen, Inc. |
Polycyclic pyrazines as potassium ion channel modulators
|
|
CN1243033C
(zh)
|
2004-07-15 |
2006-02-22 |
合肥工业大学 |
一种通过内增韧制备薄膜级聚l-乳酸共聚物的方法
|
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
CN101189239A
(zh)
|
2005-04-28 |
2008-05-28 |
休普基因公司 |
蛋白激酶抑制剂
|
|
EP1899322B1
(en)
|
2005-06-28 |
2009-09-02 |
Sanofi-Aventis |
Isoquinoline derivatives as inhibitors of rho-kinase
|
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
|
PE20070543A1
(es)
|
2005-10-06 |
2007-06-14 |
Schering Corp |
Pirazolopirimidinas como inhibidores de protein quinasas
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
GB0616747D0
(en)
|
2006-08-24 |
2006-10-04 |
Astrazeneca Ab |
Novel compounds
|
|
SA07280004B1
(ar)
*
|
2006-02-02 |
2011-10-29 |
استرازينيكا ايه بي |
ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
|
|
AU2007338410B2
(en)
|
2006-12-27 |
2012-08-16 |
Sanofi-Aventis |
Cycloalkylamine substituted isoquinoline derivatives
|
|
EP2134689B1
(en)
|
2007-03-16 |
2014-04-23 |
The Scripps Research Institute |
Inhibitors of focal adhesion kinase
|
|
WO2008117050A1
(en)
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
|
RU2009147819A
(ru)
|
2007-05-25 |
2011-06-27 |
Астразенека Аб (Se) |
Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
|
|
US8618121B2
(en)
|
2007-07-02 |
2013-12-31 |
Cancer Research Technology Limited |
9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
|
|
GB0719644D0
(en)
|
2007-10-05 |
2007-11-14 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
WO2009099601A2
(en)
|
2008-02-04 |
2009-08-13 |
Dana-Farber Cancer Institute, Inc. |
Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
|
|
GB0803018D0
(en)
|
2008-02-19 |
2008-03-26 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
US8481557B2
(en)
|
2009-04-11 |
2013-07-09 |
Array Biopharma Inc. |
Method of treatment using checkpoint kinase 1 inhibitors
|
|
US8865726B2
(en)
*
|
2009-09-03 |
2014-10-21 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
|
JP5808818B2
(ja)
|
2010-11-25 |
2015-11-10 |
ラツィオファーム・ゲーエムベーハー |
アファチニブの新規塩及び多形形態
|
|
US9345705B2
(en)
|
2011-09-15 |
2016-05-24 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
WO2013068755A1
(en)
|
2011-11-09 |
2013-05-16 |
Cancer Research Technology Limited |
5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
|
|
EP2793882A4
(en)
|
2011-12-22 |
2015-04-29 |
Threshold Pharmaceuticals Inc |
ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
|
|
CA2860665A1
(en)
|
2012-01-05 |
2013-07-11 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
JP6027230B2
(ja)
*
|
2012-05-15 |
2016-11-16 |
キャンサー・リサーチ・テクノロジー・リミテッド |
5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用
|
|
CN102675858A
(zh)
|
2012-05-22 |
2012-09-19 |
同济大学 |
一种具有形状记忆功能可降解泪管栓塞的制备方法
|
|
GB201316526D0
(en)
|
2013-09-17 |
2013-10-30 |
King S College London |
Biomarkers
|
|
WO2015077602A1
(en)
|
2013-11-22 |
2015-05-28 |
Fred Hutchinson Cancer Research Center |
Methods for identifying therapeutic targets and treating and monitoring cancers
|
|
JP2017515859A
(ja)
|
2014-05-15 |
2017-06-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
|
|
SG10201913151TA
(en)
|
2015-09-09 |
2020-03-30 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Genetic engineering of macrophages for immunotherapy
|
|
US11725247B2
(en)
|
2016-02-29 |
2023-08-15 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
WO2018191299A1
(en)
|
2017-04-10 |
2018-10-18 |
Sierra Oncology, Inc. |
Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
|
|
MX2019012176A
(es)
|
2017-04-10 |
2020-02-19 |
Sierra Oncology Inc |
Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
|
|
AU2018278336A1
(en)
|
2017-06-01 |
2020-01-16 |
Crt Pioneer Fund Lp |
Biomarkers and patient selection strategies
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
JP2021514979A
(ja)
|
2018-02-26 |
2021-06-17 |
シエラ オンコロジー, インコーポレイテッド |
Chk1阻害剤を含む癌の治療方法
|
|
CA3135165A1
(en)
|
2019-03-28 |
2020-10-01 |
Sierra Oncology, Inc. |
Methods of treating cancer with chk1 inhibitors
|
|
AU2020274164A1
(en)
|
2019-05-14 |
2021-11-25 |
Sierra Oncology, Inc. |
Methods of treating cancer using Chk1 inhibitors
|
|
CN120441567A
(zh)
|
2020-04-07 |
2025-08-08 |
Crt先锋基金有限公司 |
Chk1抑制剂的合成方法
|